106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
genitourinary-cancer-guidelines. Copyright © 2020 by American Society of Clinical Oncolog y.
All rights reserved.
ASCOOPT2012a
Abbreviations
BS, bone scintigraphy; CRPC, castration-resistant prostate cancer; CT, computerized
tomography; Mets, metastatic disease; mpMRI, multiparametric magnetic resonance imaging ;
MRI, magnetic resonance imaging ; NCCN, National Comprehensive Cancer Network; NGI;
next generation imaging ; PET, positron emission tomography; PSA, prostate specific antigen;
PSMA, prostate specific membrane antigen; WB, whole body
Source
Trabulsi EJ et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
J Clin Oncol. 2020 Jan 15 doi: 10.1200/JCO.19.02757.
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/genitourinary-cancer-guidelines.
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
CB
Consensus-
based
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
U Unknown Ins Insufficient
